Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Neurobiol Dis ; 21(2): 392-403, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16165367

ABSTRACT

Huntington disease (HD), caused by expansion >35 of a polyglutamine tract in huntingtin, results in degeneration of striatal medium spiny neurons (MSNs). Previous studies demonstrated mitochondrial dysfunction, altered intracellular calcium release, and enhanced NMDAR-mediated current and apoptosis in cellular and mouse models of HD. Here, we exposed cultured MSNs from YAC transgenic mice, expressing full-length human huntingtin with 18, 72, or 128 repeats, to a variety of apoptosis-inducing compounds that inhibit mitochondrial function or increase intracellular calcium, and assessed apoptosis 24 h later. All compounds produced a polyglutamine length-dependent increase in apoptosis, but NMDA produced the largest potentiation in apoptosis of YAC72 and YAC128 versus YAC18 MSNs. Moreover, reduction of NMDAR-mediated current and calcium influx in YAC72 MSNs to levels seen in wild-type reduced NMDAR-mediated apoptosis proportionately to wild-type levels. Our results suggest that increased NMDAR signaling plays a major role in enhanced excitotoxic MSN death in this HD mouse model.


Subject(s)
Apoptosis/physiology , Chromosomes, Artificial, Yeast/genetics , Huntington Disease/physiopathology , Neurons/pathology , Receptors, N-Methyl-D-Aspartate/metabolism , Animals , Calcium/metabolism , Cells, Cultured , Corpus Striatum/metabolism , Corpus Striatum/pathology , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Humans , Huntington Disease/metabolism , Huntington Disease/pathology , In Situ Nick-End Labeling , Mice , Mice, Transgenic , Mitochondria/drug effects , Mitochondria/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...